EQ-5D-5L and SF-6Dv2 health utilities scores of diffuse large B-cell lymphoma patients in China

Table 7 OLS regression of clinical characteristics on EQ-5D-5L and SF-6Dv2

	EQ-5D-5L				SF-6Dv2
	Coef	(95% CI)			Coef	(95% CI)
Treatment status
RR treatment	-0.017	-0.064	0.029		-0.005	-0.048	0.039
Whether on treatment
Untreated	0.004	-0.29	0.298		-0.035	-0.312	0.242
On treatment	-0.095	-0.142	-0.048	*******	-0.138	-0.182	-0.093	*******
Treatment evaluation
PR	-0.033	-0.088	0.021		-0.046	-0.097	0.005
PD	-0.104	-0.187	-0.021	*	-0.127	-0.205	-0.049	*******
Have not been evaluated	-0.055	-0.114	0.004		-0.07	-0.125	-0.015	*
IPI score
IPI = 2 (medium risk)	0.012	-0.044	0.067		0.03	-0.022	0.082
IPI = 3 ~ 5 (high risk)	-0.013	-0.07	0.045		0.009	-0.045	0.063
Unknown	0.001	-0.056	0.054		0.004	-0.048	0.056
Double-hit/Triple-hit (DHL/THL)
Yes	-0.042	-0.108	0.025		-	-	-
Unknown	-0.012	-0.08	0.056		-	-	-
Double-expressor (DEL)
Yes	-0.012	-0.058	0.034		-0.031	-0.072	0.009
Unknown	-0.031	-0.1	0.038		-0.021	-0.065	0.023
TP53 mutation
Yes	-0.017	-0.073	0.039		-0.005	-0.057	0.048
Unknown	-0.02	-0.068	0.028		-0.018	-0.063	0.027
MYD88 mutation and/or CD79b mutation
CD79b mutation	-0.004	-0.124	0.117		0.02	-0.093	0.132
MYD88 mutation	-0.093	-0.175	-0.01	*	-0.082	-0.16	-0.005	*
Both	-0.025	-0.104	0.053		-0.009	-0.083	0.065
Unknown	0.01	-0.039	0.06		0.011	-0.035	0.057
Ann Arbor staging
Stage II	-0.018	-0.08	0.045		-0.043	-0.102	0.016
Stage III	-0.003	-0.074	0.069		-0.027	-0.094	0.04
Stage IV	-0.076	-0.142	-0.011	*	-0.093	-0.155	-0.032	**
Unknown	0.034	-0.107	0.04		-0.033	-0.102	0.036
Complication
Have at least one complication	-0.035	-0.07	0	*	-0.054	-0.087	-0.021	*******
Constant	0.959	0.904	1.014	*******	0.789	0.737	0.84	*******

Reference category: initial treatment, off treatment, CR, IPI = 0 ~ 1 (low risk), no DHL/THL, no DEL, no TP53 mutation, neither MYD88 mutation nor CD79b mutation, Ann Arbor staging: Stage I, no complication
^*P < 0.05, **P < 0.01, ***P < 0.001

ISSN: 1477-7525